Neos Therapeutics (NEOS) Posts Wider-than-Expected Q3 Loss

Neos Therapeutics (NASDAQ: NEOS) reported Q3 EPS of ($0.77), $0.19 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $221 thousand versus the consensus estimate of $800 thousand.

For earnings history and earnings-related data on Neos Therapeutics (NEOS) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c